Literature DB >> 30550781

NKG2A, a New Kid on the Immune Checkpoint Block.

John B Haanen1, Vincenzo Cerundolo2.   

Abstract

One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8+ T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30550781     DOI： 10.1016/j.cell.2018.11.048

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  16 in total

1.  Downregulated cytotoxic CD8+ T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids.

Authors:  Heng Xu; Zhu Zhu; Jian Hu; Jiawei Sun; Yan Wo; Xianshu Wang; Hongzhi Zou; Bin Li; Yixin Zhang
Journal:  Cell Mol Immunol       Date:  2022-01-17       Impact factor: 22.096

Review 2.  Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.

Authors:  Xiang-Yuan Luo; Kong-Ming Wu; Xing-Xing He
Journal:  J Exp Clin Cancer Res       Date:  2021-05-18

Review 3.  The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.

Authors:  Haoyu Sun; Cheng Sun
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

4.  CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis.

Authors:  Guangyong Sun; Xinyan Zhao; Mingyang Li; Chunpan Zhang; Hua Jin; Changying Li; Liwei Liu; Yaning Wang; Wen Shi; Dan Tian; Hufeng Xu; Yue Tian; Yongle Wu; Kai Liu; Zhongtao Zhang; Dong Zhang
Journal:  Nat Commun       Date:  2021-01-28       Impact factor: 14.919

Review 5.  Immune dysregulation and system pathology in COVID-19.

Authors:  Muhammad Jamal; Hina Iqbal Bangash; Maria Habiba; Yufei Lei; Tian Xie; Jiaxing Sun; Zimeng Wei; Zixi Hong; Liang Shao; Qiuping Zhang
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 6.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

7.  The Immunopathobiology of SARS-CoV-2 Infection.

Authors:  Milankumar Patel; Farah Shahjin; Jacob D Cohen; Mahmudul Hasan; Jatin Machhi; Heerak Chugh; Snigdha Singh; Srijanee Das; Tanmay A Kulkarni; Jonathan Herskovitz; Douglas D Meigs; Ramesh Chandra; Kenneth S Hettie; R Lee Mosley; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  FEMS Microbiol Rev       Date:  2021-11-23       Impact factor: 16.408

Review 8.  Drug repurposing against COVID-19: focus on anticancer agents.

Authors:  Gennaro Ciliberto; Rita Mancini; Marco G Paggi
Journal:  J Exp Clin Cancer Res       Date:  2020-05-12

9.  TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.

Authors:  Brenda De Keersmaecker; Sofie Claerhout; Javier Carrasco; Isabelle Bar; Jurgen Corthals; Sofie Wilgenhof; Bart Neyns; Kris Thielemans
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

Review 10.  Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.

Authors:  Inès Zidi
Journal:  Hum Immunol       Date:  2020-10-07       Impact factor: 2.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.